The development of multiple drug therapies with kidney protective effects additive to those of renin-angiotensin-aldosterone system (RAAS) inhibitors for persons living with type 2 diabetes and chronic kidney disease (CKD) has resulted in clinicians currently having a choice of 3 effective options: sodium/glucose cotransporter 2 (SGLT2) inhibitors,1-3 nonsteroidal mineralocorticoid antagonists (nsMRAs),4,5 and glucagon-like peptide-1 receptor agonists (GLP-1RAs).6 Because these novel drugs were developed in parallel, they were each compared only with RAAS inhibitor treatment in their respective phase 3 clinical trials, resulting in a lack of data directly comparing efficacy or evaluating combination therapy.